IDegLira lowers the hormone glucagon after meals more than liraglutide alone, but not more than insulin alone, indicating that glucagon suppression is not the main reason IDegLira improves blood sugar control.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review would determine whether IDegLira consistently suppresses glucagon more than liraglutide alone across trials and whether this effect correlates with glycemic outcomes.
A systematic review and meta-analysis of all RCTs measuring postprandial glucagon (iAUC0-4h) in adults with type 2 diabetes treated with IDegLira, liraglutide, or insulin degludec, pooling standardized mean differences and assessing heterogeneity by baseline glucagon levels and treatment duration.
A double-blind RCT would confirm whether IDegLira’s glucagon suppression is directly attributable to the combination and not to unblinded bias.
A double-blind, parallel-group RCT of 120 adults with type 2 diabetes (HbA1c 7.5–9.0%) randomized 1:1:1 to IDegLira, liraglutide, or insulin degludec, with plasma glucagon measured at 9 time points during a standardized meal test at baseline and 26 weeks, using blinded assays and standardized diet.
A prospective cohort would determine whether glucagon suppression with IDegLira predicts long-term glycemic durability or beta cell preservation.
A multicenter prospective cohort study of 400 adults with type 2 diabetes initiating IDegLira, measuring postprandial glucagon (iAUC0-4h) at baseline, 6, 12, and 24 months, and tracking HbA1c, insulin dose, and beta cell function over 5 years.
A case-control study could identify whether patients with greater glucagon suppression on IDegLira have distinct GLP-1 receptor variants or metabolic profiles.
A case-control study comparing 80 adults with type 2 diabetes who showed >20% glucagon suppression on IDegLira (cases) to 80 matched controls with <5% suppression, assessing GLP-1R polymorphisms, fasting glucagon, and insulin sensitivity.
A cross-sectional study could describe the association between glucagon levels and IDegLira use at a single time point.
A cross-sectional analysis of 300 adults with type 2 diabetes on IDegLira, liraglutide, or insulin degludec, measuring postprandial glucagon (iAUC0-4h) during a single standardized meal test.